A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution

References

• Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354(9179):630–635. doi:10.1016/S0140-6736(98)12387-5.
   PubMed Web of Science ®Google Scholar
• Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351(19):1962–1971. doi:10.1056/NEJMoa040979.
   PubMed Web of Science ®Google Scholar
• Chidambaram JD, Alemayehu W, Melese M, et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA. 2006;295(10):1142–1146. doi:10.1001/jama.295.10.1142.
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet. 2005;366(9493):1296–1300. doi:10.1016/S0140-6736(05)67529-0.
   PubMed Web of Science ®Google Scholar
• Burton MJ, Holland MJ, Makalo P, et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet (London, England). 2005;365(9467):1321–1328. doi:10.1016/S0140-6736(05)61029-X.
   PubMed Web of Science ®Google Scholar
• Edwards T, Harding-Esch EM, Hailu G, et al. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin. Trop Med Int Health: TM IH. 2008;13(4):556–565. doi:10.1111/j.1365-3156.2008.02034.x.
   PubMed Web of Science ®Google Scholar
• Ayele B, Gebre T, Moncada J, et al. Risk factors for ocular chlamydia after three mass azithromycin distributions. PLoS Negl Trop Dis. 2011;5(12):e1441. doi:10.1371/journal.pntd.0001370.
   PubMed Web of Science ®Google Scholar
• Cajas-Monson LC, Mkocha H, Munoz B, Quinn TC, Gaydos CA, West SK. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania. PLoS Negl Trop Dis. 2011;5(3):e978. doi:10.1371/journal.pntd.0001370.
   PubMed Web of Science ®Google Scholar
• Melese M, Chidambaram JD, Alemayehu W, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA. 2004;292(6):721–725. doi:10.1001/jama.292.6.721.
   PubMed Web of Science ®Google Scholar
• Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA. 2008;299(7):778–784. doi:10.1001/jama.299.7.778.
   PubMed Web of Science ®Google Scholar
• Lakew T, House J, Hong KC, et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis. 2009;3(2):e376. doi:10.1371/journal.pntd.0000376.
   PubMed Web of Science ®Google Scholar
• Basilion EV, Kilima PM, Mecaskey JW. Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Trans R Soc Trop Med Hyg. 2005;99(1):6–12. doi:10.1016/j.trstmh.2004.01.014.
   PubMed Web of Science ®Google Scholar
• Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65:477–483.
   PubMed Web of Science ®Google Scholar
• Diamant J, Benis R, Schachter J, et al. Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol. 2001;8(2–3):109–117.
   PubMedGoogle Scholar
• Chin SA, Morberg DP, Alemayehu W, et al. Chlamydial ompA diversity in trachoma-hyperendemic communities treated with azithromycin. Am J Epidemiol. 2018. doi:10.1093/aje/kwy071.
   Web of Science ®Google Scholar
• West S, Munoz B, Bobo L, et al. Nonocular Chlamydia infection and risk of ocular reinfection after mass treatment in a trachoma hyperendemic area. Invest Ophthalmol Vis Sci. 1993;34(11):3194–3198.
   PubMed Web of Science ®Google Scholar
• Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet. 2003;362(9379):198–204. doi:10.1016/S0140-6736(03)13909-8.
   PubMed Web of Science ®Google Scholar
• West ES, Munoz B, Mkocha H, et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci. 2005;46(1):83–87. doi:10.1167/iovs.04-0327.
   PubMed Web of Science ®Google Scholar
• Katz J, Zeger SL, Tielsch JM. Village and household clustering of xerophthalmia and trachoma. Int J Epidemiol. 1988;17:865–869.
   PubMed Web of Science ®Google Scholar
• Bailey R, Osmond C, Mabey DC, Whittle HC, Ward ME. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. Int J Epidemiol. 1989;18:944–951.
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Turner VM, Mmbaga BB, Taylor HR. The epidemiology of trachoma in central Tanzania. Int J Epidemiol. 1991;20:1088–1092.
   PubMed Web of Science ®Google Scholar
• Bailey RL, Hayes L, Pickett M, Whittle HC, Ward ME, Mabey DC. Molecular epidemiology of trachoma in a Gambian village. Br J Ophthalmol. 1994;78:813–817.
   PubMed Web of Science ®Google Scholar
• Polack SR, Solomon AW, Alexander ND, et al. The household distribution of trachoma in a Tanzanian village: an application of GIS to the study of trachoma. Trans R Soc Trop Med Hyg. 2005;99(3):218–225. doi:10.1016/j.trstmh.2004.06.010.
   PubMed Web of Science ®Google Scholar
• Broman AT, Shum K, Munoz B, Duncan DD, West SK. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. Invest Ophthalmol Vis Sci. 2006;47(1):99–104. doi:10.1167/iovs.05-0326.
   PubMed Web of Science ®Google Scholar
• Yohannan J, He B, Wang J, et al. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment. Invest Ophthalmol Vis Sci. 2014;55(7):4144–4150. doi:10.1167/iovs.14-14148.
   PubMedGoogle Scholar
• Miller K, Schmidt G, Melese M, et al. How reliable is the clinical exam in detecting ocular chlamydial infection? Ophthalmic Epidemiol. 2004;11(3):255–262. doi:10.1080/09286580490514577.
   PubMed Web of Science ®Google Scholar
• Lee JS, Munoz BE, Mkocha H, Gaydos CA, Quinn TC, West SK. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children. PLoS Negl Trop Dis. 2014;8(4):e2761. doi:10.1371/journal.pntd.0002761.
   PubMed Web of Science ®Google Scholar
• Bailey R, Duong T, Carpenter R, Whittle H, Mabey D. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect. 1999;123:479–486.
   PubMed Web of Science ®Google Scholar
• Shekhawat N, Mkocha H, Munoz B, et al. Cohort and age effects of mass drug administration on prevalence of trachoma: a longitudinal study in rural Tanzania. Invest Ophthalmol Vis Sci. 2014;55(4):2307–2314. doi:10.1167/iovs.13-12701.
   PubMed Web of Science ®Google Scholar
• Grassly NC, Ward ME, Ferris S, Mabey DC, Bailey RL. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis. 2008;2(12):e341. doi:10.1371/journal.pntd.0000326.
   PubMed Web of Science ®Google Scholar
• Gebresillasie S, Tadesse Z, Shiferaw A, et al. Inter-Rater agreement between trachoma graders: comparison of grades given in field conditions versus grades from photographic review. Ophthalmic Epidemiol. 2015;22(3):162–169. doi:10.3109/09286586.2015.1035792.
   PubMed Web of Science ®Google Scholar